ArticleCancer immunology, immunotherapy : CII2025
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- TNC-targeted CAR-macrophage therapy alleviates liver fibrosis in mice.Military Medical Research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
To generate CARCIK cells with enhanced targeting and penetration of solid tumors, we have designed new CAR molecules against tenascin C (TNC), an extracellular matrix and surface molecule, overexpressed in several tumor types. Two different anti-TNC CAR constructs were generated, sharing the anti-TNC scFv domain, fused to the CD3ζ fragment, but differing in co-signaling domains: CAR-TNC4 carrying the 4-1BB and CAR-TNC5 the CD28 and OX40 domains. Both CARs were introduced into cytokine-induced killer cells (CIK) by co-transfection with the sleeping beauty transposase plasmid. CARCIK-TNC cells were cytotoxic against TNC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.